Abstract: Disclosed are chimeric antigen receptors, and cells modified to express one or more proteins comprising regions of a chimeric antigen receptor (CAR). The CARs comprise an antigen binding region, a transmembrane region and a CD6-derived signalling region, wherein the CD6-derived signalling region comprises a GADS binding motif and a SLP-76 binding motif. The CD6-derived signalling region may be between 20 and 60 amino acid residues in length. The CARs exhibit increased cell activation and increased target cell killing when incorporated in CAR T cells. Also disclosed are nucleic acids encoding such CARs, and collections of nucleic acids. There are also provided medical uses of the CARs, cells, or nucleic acids, and methods of treating a condition or infection.

Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.